Alcohol Disorders Clinical Trial
Official title:
Interest of Cognitive Remediation for the Reduction of Consumption in Alcohol Disorders
The individual and societal cost of alcohol use disorders (TUAL), present in 10% of the population in France, is considerable. Despite psychotherapeutic and drug addiction treatment, the relapse rate remains very high, partly because of their very frequent cognitive disorders. In fact, more than 75% of TUAL patients present to varying degrees neuropsychological alterations that are only rarely detected and never treated. However, these cognitive disorders limit the benefit of psychotherapeutic care, reduce compliance with pharmacological treatments and hinder the patient's ability to change his behavior with respect to alcohol. An innovative way to promote the maintenance of the therapeutic contract, and therefore to reduce alcohol consumption in these patients, would be to improve their cognitive functioning. The objective of this study is to measure the efficacy of a non-drug treatment, based on a specific and personalized cognitive remediation program, compared to a standard treatment in Day Hospitalization, in order to reduce the rate of relapse very high in TUAL. It is a randomized, single-blind study with two parallel groups of patients with post-weaning neuropsychological disorders: REMED (cognitive remediation) and CONTROL (usual care).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04502589 -
Open Label Pilot Study of Perampanel for the Treatment of Alcohol Use Disorder
|
Phase 1/Phase 2 | |
| Completed |
NCT02030288 -
Relational Agent for Alcohol Screening and Treatment
|
N/A |